Bright Minds Biosciences News

Bright Minds Biosciences | 6-K: Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

Nov 22, 2024 00:34

Bright Minds Biosciences | 6-K: Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

Nov 6, 2024 01:20

Bright Minds Biosciences | 6-K: Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study

Oct 22, 2024 04:06

Bright Minds Biosciences | 6-K: Bright Minds Biosciences Announces $35 Million Non-Brokered Private Placement

Oct 19, 2024 04:05

Bright Minds Biosciences | 6-K: Unaware of any Material Changes

Oct 16, 2024 23:47

Bright Minds Biosciences | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Oct 16, 2024 23:42

Bright Minds Biosciences | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Oct 3, 2024 23:41

Bright Minds Biosciences | 6-K: Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

Sep 13, 2024 01:03

Bright Minds Biosciences | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Dec 26, 2023 13:00

Bright Minds Biosciences | 6-K: Bright Minds Announces Non-Brokered Private Placement Fully Subscribed By Management

Dec 8, 2023 19:00

Bright Minds Biosciences | 6-K: Condensed Consolidated Interim Financial Statements for the three and nine months ended June 30, 2023 and 2022

Aug 15, 2023 07:07

Bright Minds Biosciences | 6-K: Bright Minds Biosciences Announces Positive qEEG Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Aug 9, 2023 04:24

Bright Minds Biosciences | 6-K: Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Jul 21, 2023 01:49

Bright Minds Biosciences | 6-K: Bright Minds Announces Effective Date of Share Consolidation

Jul 13, 2023 04:55

Bright Minds Biosciences | 6-K: Bright Minds Announces Proposed Share Consolidation

Jun 23, 2023 03:36

Bright Minds Biosciences | 6-K: MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE SECOND QUARTER ENDED MARCH 31, 2023

May 16, 2023 05:15

Bright Minds Biosciences | 6-K: Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

Apr 20, 2023 03:41

Bright Minds Biosciences | 6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]

Apr 10, 2023 20:15

Bright Minds Biosciences | 6-K: Bright Minds Biosciences to Hold Annual General Meeting on March 24, 2023

Mar 3, 2023 03:37

Bright Minds Biosciences | 6-K: Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Feb 28, 2023 06:20